The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages

  Mujtaba, Muhammad A ^a   Goggins, William ^c   Lobashevsky, Andrew ^b   Sharfuddin, Asif A ^a   Yaqub, Muhammad S ^a   Mishler, Dennis P ^a   Brahmi, Zacharie ^b   Higgins, Nancy ^b   Milgrom, Martin M ^c   Diez, Alejandro ^a   Taber, Tim ^a  

^a Division of Transplant   (United States)

^b Transplantation Immunology Laboratory   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; Desensitization; Donor specific antibodies; Flow cytometry; Graft survival; Kidney transplant

Indexed keywords

DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLOOD GROUP TYPING; CLINICAL ARTICLE; CLINICAL EVALUATION; CORTICOSTEROID THERAPY; DONOR SELECTION; FEMALE; FLOW CYTOMETRY; FLOW CYTOMETRY CROSSMATCH ANALYSIS; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; STEROID THERAPY; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME;

EID: 79551718171     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01341.x     Document Type: Article

References (47)

1. The OPTN. 2007; Available from.
2. Reinsmoen NL, Nelson K, Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol 2004: 13: 63.
3. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. [see comment]. Transplantation 2008: 27: 86.
4. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: whose problem is it? Front Biosci 2008: 13: 1396.
5. Akalin E, Pascual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol, 2006: 1: 433.
6. Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005: 66: 334.
7. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007: 7: 864.
8. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003: 3: 665.
9. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match - positive kidney transplant recipients. Hum Immunol 2005: 66: 359.
10. Lee P-C, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002: 74: 1192.
11. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003: 25: 119.
12. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004: 4: 1033.
13. Crew RJ, Ratner LE. Overcoming immunologic incompatibility: transplanting the difficult to transplant patient. Semin Dial 2005: 18: 474.
14. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int 2006: 19: 87.
15. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004: 8: 535.
16. Andrea AZ, Robert AM, Mary SL. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol Rev 2005: 5: 373.
17. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006: 6: 459.
18. Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FHJ, Reed EF. 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation. Tissue Antigens 2007: 69(s1): 160.
19. Akalin E, Dinavahi R, Friedlander R et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol [Clinical Trial Research Support, Non-U.S. Gov't]. 2008: 3: 1160.
20. Gloor J, Stegall MD. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol 2010: 6: 297. [].
21. Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009: 87: 268.
22. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003: 3: 1488.
23. Lefaucheur C, Nochy D, Hill GS et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007: 7: 832.
24. Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: I. incidence, serology and clinical characteristics. Transplantation 2001: 71: 652.
25. Lobashevsky AL, Senkbeil RW, Shoaf J et al. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant 2000: 14: 533.
26. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009: 87: 1681.
27. Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PTH. Clinical significance of anti-HLA antibodies detected by Luminex®: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 2009: 70: 595.
28. Everly MJ, Rebellato LM, Ozawa M et al. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010: 89: 962 DOI
29. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008: 85: 1200.
30. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009: 87: 1505.
31. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 2009: 162: 1.
32. Mizutani K, Terasaki P, Hamdani E et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007: 7: 1027.
33. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007: 7: 2371.
34. Zeevi A, Lunz JG III, Shapiro R et al. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol 2009: 70: 645.
35. Gloor JM, Winters JL, Cornell LD et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010: 10: 582.
36. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005: 66: 364.
37. Wen R, Wu V, Dmitrienko S, Yu A, Balshaw R, Keown PA. Biomarkers in transplantation: prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int 2006: 70: 1474.
38. Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003: 76: 1444.
39. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006: 6: 346.
40. Mai ML, Ahsan N, Wadei HM et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009: 87: 227.
41. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009: 70: 574 [doi: DOI: ].
42. Lobashevsky AL, Higgins NG. 41-P: predictive values (PV) of class I and class II antibodies (Ab) detected by luminex. Hum Immunol 2009: 70(Suppl 1): S32 [doi: DOI: ].
43. Issa N, Cosio FG, Gloor JM et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008: 86: 681.
44. Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006: 6: 1841.
45. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008: 8: 492.
46. Gloor JM, Sethi S, Stegall MD et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007: 7: 2124.
47. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol [DOI: ], 2008: 69: 591.